Cargando…
Involvement of interleukin 6 in SARS-CoV-2 infection: siltuximab as a therapeutic option against COVID-19
The aim of the study was to explore the involvement of interleukin 6 in SARS-CoV-2 infection, and to position the drug siltuximab in the management of severe forms of COVID-19. A bibliographic search was performed in Pubmed on the immune response to the disease, and in ClinicalTrials.gov on clinical...
Autores principales: | Palanques-Pastor, Tomás, López-Briz, Eduardo, Poveda Andrés, José Luis |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7447248/ https://www.ncbi.nlm.nih.gov/pubmed/32499314 http://dx.doi.org/10.1136/ejhpharm-2020-002322 |
Ejemplares similares
-
Siltuximab (CNTO 328): a promising option for human malignancies
por: Chen, Runzhe, et al.
Publicado: (2015) -
Experience with the use of siltuximab in patients with SARS-CoV-2 infection
por: Meira, Fernanda, et al.
Publicado: (2021) -
Haematology patients infected with SARS-CoV-2, pretreated with eculizumab or siltuximab, develop oligosymptomatic disease
por: Iluta, Sabina, et al.
Publicado: (2022) -
Afebrile Pneumonia in a Patient With Multicentric Castleman Disease on Siltuximab: Infection Without Fever on Anti-Interleukin-6 Therapy
por: Cohen, Philip R, et al.
Publicado: (2020) -
Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19
por: Gritti, Giuseppe, et al.
Publicado: (2021)